ClinicalTrials.gg
CompletedNCT03452696CALCIMIPUpdated Apr 8, 2019

Clinical Trial to Evaluate the Tolerability and Efficacy of Microencapsulated Calcium Carbonate

A Phase 3 interventional study of Calcium supplement in Hypocalcemia; Dietary, sponsored by Instituto Palacios. Completed at 1 site in Spain. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by Instituto Palacios · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Female
01

Study summary

Interventional Clinical trial with food supplement, randomized, double-blind, comparative between microencapsulated calcium, calcium carbonate salts standardized and calcium citrate, in a population of postmenopausal women, lasting 1 month.

02

Conditions studied

  • Hypocalcemia; Dietary

Browse trials for

03

In context

Hypocalcemia

98 studies on the registry are indexed under Hypocalcemia; 16 are open to participants now.

This study's enrollment of 208 is above the median of 84 across 66 interventional studies indexed under Hypocalcemia.

Browse Hypocalcemia studies →

Lead sponsor

Instituto Palacios is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • woman
  • Low contribution of elemental calcium in the daily diet

Exclusion criteria

Exclusion Criteria:

  • to the active substances or to any of the
  • Renal insufficiency
  • History of kidney or urinary stones
  • Use in the last month of diuretics (furosemide, ethacrynic acid), aluminum salts and / or thyroid hormones
  • Use of any other drug or experimental device during the 30 days prior to the selection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Calcium supplement 10/90

    Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.

    Dietary Supplement: Calcium supplement

  • Experimental
    Calcium supplement 5/95

    Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element

    Dietary Supplement: Calcium supplement

  • Active comparator
    Calcium carbonate supplement

    1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.

    Dietary Supplement: Calcium supplement

  • Active comparator
    Calcium citrate supplement

    1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element

    Dietary Supplement: Calcium supplement

Interventions

  • Dietary supplementCalcium supplement

    Calcium supplement for low contribution of elemental calcium in the daily diet

06

What researchers measure

Primary outcomes

  1. Gastric symptoms

    Using the Gastrointestinal Symptom Rating Scale (GRS). The scale measures constipation, diarrhea, windiness, swelling, nausea, reflux, pain and burning. The patient will have to choose the most appropriate response among those proposed. "Not at all" is the better outcome and "very strong discomfort" is the worst outcome

    Time frame: 1 month

Secondary outcomes

  1. Changes in bone markers

    Bone Marker Analysis (CTx and P1NP) will be performed

    Time frame: Basal and 1 month

07

Study locations

1 site
  • Instituto Palacios
    Madrid, 28009, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03452696
Lead sponsor
Instituto Palacios
Collaborators
Nexentia S.A.S.
Responsible party
Dr. Santiago Palacios (Principal Investigator, Instituto Palacios) — Principal investigator
First posted
Mar 2, 2018
Start date
Jun 15, 2018
Primary completion
Mar 28, 2019
Completion
Apr 3, 2019
Last update
Apr 8, 2019

Study contacts

Santiago Palacios, PI
principal investigator · Instituto Palacios

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcium Supplement

Start the discussion